Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA ® (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress

Dateline City: KENILWORTH, N.J. Data Comparing KEYTRUDA to Chemotherapy Shows Continued Benefit with Follow-Up Beyond 2.5 Years  in Patients with Ipilimumab-Refractory Advanced MelanomaKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from the final overall survival (OS) analysis from the KEYNOTE-002 study investigating the use of KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, compared to investigator-choice chemotherapy with a crossover to KEYTRUDA design, in patients with ipilimumab-refractory advanced melanoma.Language: EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer Melanoma MSD Source Type: news